^
Association details:
| Biomarker: | MAP2K1 K57T |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Vectibix (panitumumab) (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer
Excerpt:
Exogenous expression of either K57T (identified in the patient) or K57N (identified in the cell line) mutant MEK1, but not WT MEK1, in an independent RAS WT colorectal cancer cell line, LIM1215, was sufficient to confer resistance to cetuximab or panitumumab
DOI:
10.1158/2159-8290.CD-15-1283
